Skip to content
Research Article Open access CC BY 4.0

Lenvatinib in Anaplastic Thyroid Carcinoma (ATC) in a Tertiary Caner Hospital- a Single Institute Experience

Rakesh Sharma, P. S. Dattatreya, A. V. S. Suresh, Ch Mohana Vamsy

Journal of Cancer and Tumor International · pp. 7–10 · Published 12 Jul 2021

10.9734/jcti/2021/v11i430156

Abstract

Anaplastic Thyroid Carcinoma (ATC) is an aggressive rare form of caner with limited treatment options and short survival. In view of initial case reports have shown some good clinical response with lenvatinib, we used the same in our institute. We are presenting a retrospective series of 4 cases between 2018-2021. It showed very promising results with 75% showing clinically meaningful regression of tumor. Hypertension is the most common side effect, which should be aggressively managed. We feel that, lenvatinib remains a safe and effective option to explore in patients with refractory anaplastic thyroid carcinoma.

Anaplastic thyroid carcinoma lenvatinib India

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.